Ambulance magnesium treatment fails to improve stroke outcome
American Stroke Association Meeting Report: Abstract: 214 (Rm. 27)
- Giving magnesium to stroke patients in an ambulance soon after symptoms began did not reduce the severity of disability measured 3 months later.
- The study successfully demonstrated that up to three-quarters of stroke patients calling 9-1-1 early can be started on treatment in the first “golden hour” after symptoms emerge.
- This early-treatment system opens the door to testing other possibly brain-saving therapies.
SAN DIEGO, Feb. 13, 2014 – Giving intravenous magnesium to stroke patients soon after the start of symptoms, in an attempt to protect brain cells deprived of oxygen, failed to improve stroke-related disability 3 months later, according to research presented at the American Stroke Association’s International Stroke Conference 2014.
Investigators showed that paramedics can successfully deliver intravenous medications to most stroke patients within an hour after symptoms begin. This is the “golden hour” the time in which patients have the best chance to survive and avoid long-term neurological damage.
“We hoped magnesium would be beneficial, but in any case the study was a success in demonstrating we can get a drug to patients in this early time frame when there is the greatest amount of threatened brain tissue that might still be saved. There are lots of other promising agents in the pipeline that could be helpful and we now have a system for testing and using them,” said Jeffrey L. Saver, M.D., principal investigator and professor of neurology and director of the stroke center at UCLA.
Currently, the only immediate treatment for clot-caused strokes is the clot-dissolving medication tissue plasminogen activator (tPA). However, this drug can’t be given until the patient arrives at the hospital and a clot is confirmed by CT scan or other imaging.
“Giving tPA in the ambulance before brain imaging is not an option – it could harm patients having a bleeding type of stroke. Neuroprotective drugs can be delivered in the field as they are safe for both types of stroke,” Saver said.
The Field Administration of Stroke Therapy – Magnesium Phase 3 Clinical Trial (FAST-MAG) tested whether IV magnesium, a potential neuroprotective agent, could be delivered in a timely manner and was effective in improving the neurological outcome of patients. Magnesium was chosen because, in animal studies, it dilates blood vessels in the brain, increasing blood flow, and counters the dangerous calcium overload that occurs in cells that are deprived of oxygen. In smaller human trials, magnesium given up to 12 hours after a stroke showed neither harm nor benefit overall, but there were indications that it was helpful in the small number of patients who received it within a few hours of stroke onset.
In the current study, IV magnesium proved to be safe, resulting in no more serious adverse reactions than placebo infusions. However, there was no benefit in outcome. Ninety days after the stroke, the average level of disability in both magnesium and placebo patients was 2.7 on the modified Rankin scale, indicating between a slight and moderate level of disability in which patients are unable to carry out their previous activities without assistance.
FAST-MAG involved collaboration between 315 ambulances, 40 emergency medical service agencies, 60 receiving hospitals, and 2,988 paramedics in Los Angeles and Orange Counties in California. Between 2005 and 2012, paramedics evaluated and began infusions of study medications to 1,700 patients (42.7 percent female, average age 69) within 2 hours of symptom onset.
In the study, the median time for receiving treatment was 45 minutes after symptoms began, and 74 percent of patients were started on treatment within an hour.
“The FAST-MAG investigators are enormously indebted to the paramedics who implemented the trial and showed incredible skill and dedication as first responders for this devastating brain condition,” Saver said.
“Similarly the National Institute of Neurological Disorders and Stroke (NINDS) is extremely grateful to the investigators, emergency medical technicians, and patients who participated in this landmark study demonstrating how to test therapies in stroke patients before they arrive at the hospital,” said Walter Koroshetz, M.D., Deputy Director of the NIH NINDS, the sponsor of the FAST-MAG study. “NINDS has just set up a new national stroke trials network which can incorporate the lessons learned in FAST-MAG, but also increase the likelihood that the treatments we test will improve patients’ lives.”
Co-authors are Marc Eckstein, M.D.; Samuel Stratton, M.D., M.P.H.; Frank Pratt, M.D.; Scott Hamilton, Ph.D.; Robin Conwit, M.D.; David Liebeskind, M.D.; Patrick Lyden, M.D.; Nerses Sanossian, M.D.; Gene Sung, M.D.; Ian Kramer, M.D.; Gary Moreau, M.D.; Robert Goldweber, M.D.; and Sidney Starkman, M.D.; writing for the FAST-MAG investigators and coordinators.
Author disclosures are on the abstract.
The study was funded by the National Institute of Neurological Disorders and Stroke.
- All downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release link located at http://newsroom.heart.org/news/ambulance-magnesium-treatment-fails-to-improve-stroke-outcome?preview=61dca0f34d1dd42e05b1507a422f4323.
- Follow news from ASA International Stroke Conference 2014 via Twitter: @HeartNews #ISC14.
Get more information on:
Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
Note: Actual presentation is 11 a.m. PT, Thursday, February 13, 2014.